Bayer Aktiengesellschaft (BAYND.XC)
| Previous close | 27.69 |
| Open | 27.69 |
| Bid | 27.04 x 0 |
| Ask | 27.41 x 0 |
| Day's range | 27.69 - 27.69 |
| 52-week range | 24.99 - 54.32 |
| Volume | |
| Avg. volume | 684 |
| Market cap | 27.208B |
| Beta (5Y monthly) | 0.97 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.11 (0.40%) |
| Ex-dividend date | 29 Apr 2024 |
| 1y target est | N/A |
- Simply Wall St.
Further weakness as Bayer (ETR:BAYN) drops 3.3% this week, taking one-year losses to 49%
It's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly...
- Bloomberg
Bayer Calls Roundup Suits Existential Threat to Company, Farming
(Bloomberg) -- Bayer AG Chief Executive Officer Bill Anderson said the wave of lawsuits over its Roundup weedkiller is an “existential” threat to the company and farmers, ratcheting up the stakes as it considers a controversial legal maneuver.Most Read from BloombergSingapore Air Changes Seatbelt Rules After Fatal TurbulenceSpaceX Weighs Plan to Sell Shares at $200 Billion ValuationThe Rise and Fall of Simon Sadler's Segantii, One of Asia's Most Successful Hedge FundsChina’s $538 Billion Deposit
- Zacks
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.
